Clinical Trial Update: CHAMP: Study of NVK-002 in Children With Myopia [Phase 3]

View source ↗

Summary

A Phase 3 trial (CHAMP) evaluating NVK-002 in children with myopia has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• NVK-002

Snippet

Sponsor: Vyluma, Inc. | Conditions: Myopia | Phase 3 | Status: COMPLETED | Results posted: 2024-11-27